Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Clene Inc
(NQ:
CLNN
)
0.4251
-0.0049 (-1.14%)
Streaming Delayed Price
Updated: 2:04 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Clene Inc
< Previous
1
2
3
Next >
Study Suggests Metabolism Issues After Spinal-Cord Injury Result from Disturbed Neuronal Activity
May 03, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Spotlighted in a Recent ‘From Lab to Launch’ Podcast Release
May 01, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Presents Findings on Phase 2 VISIONARY-MS LTE at American Academy of Neurology Annual Meeting
May 01, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Continues Development of Lead Drug Candidate CNM Au8(R) for Neurodegenerative Diseases including Parkinson’s Disease
April 22, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Study Results for CNM-Au8 as Multiple Sclerosis Treatment Presented at AAN Conference
April 17, 2024
Via
Investor Brand Network
Study Identifies Three Distinct Subtypes of Multiple Sclerosis
April 15, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Looking to Advance Discussions for Accelerated Approval, New NDA for CNM-Au8(R) in 2024
April 11, 2024
Via
Investor Brand Network
Exposures
Product Safety
Clene Inc. (NASDAQ: CLNN) has Emerged as a Leader in the Neurodegenerative Field Utilizing a Novel Nanotherapeutic Drug
April 09, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Announces Publication of “Protein Corona Composition of Gold Nanocatalysts” in ACS Pharmacology & Translational Science
April 02, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MS
March 26, 2024
Via
Investor Brand Network
New Study Leverages Real-World Data to Assess Differences in Parkinson’s Progression
March 25, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) Work in Nanotechnology Highlighted in ‘First in Human’ Podcast
March 19, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Publication of Peer-Reviewed Research for Investigational Drug CNM-Au8(R)
March 15, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces FY 2023 Results, Recent Operating Highlights
March 13, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Upcoming 36th Annual Roth Conference
March 07, 2024
Via
Investor Brand Network
A Comparison Between ALS, Parkinson’s Disease
March 01, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN), Subsidiary Report Positive Clinical Results of CNM-Au8 Treatment at MS Forum
February 29, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Aiming to Address Neurodegenerative Diseases from a New Angle
February 27, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Statistically Significant Results from Independent Analyses of ALS Patient Data
February 22, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Eyes ‘Rarely Seen’ Clinically Significant Improvement in MS Patients
February 20, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Revolutionizes Approach to Restore Neuronal Health in Neurodegenerative Disease with CNM-Au8(R)
February 13, 2024
Via
Investor Brand Network
New MRI Procedure Eases Multiple Sclerosis Diagnosis
February 12, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive Interview
February 06, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS
February 06, 2024
Via
Investor Brand Network
Clene Inc. announces positive results from CNM-Au8 results from MS trial
February 05, 2024
Clene Inc (NASDAQ:CLNN) CEO Rob Etherington joined Steve Darling from Proactive to share news regarding the latest findings from the long-term open-label extension (LTE) of the VISIONARY-MS trial.
Via
TheNewswire.com
BioMedNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Produces ‘Significant and Very Promising Effect’ in Parkinson’s, MS Patients
February 02, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Unites Physics, Chemistry, Material Science, and Biology to Address Neurodegenerative Diseases With The Company’s Unique CNM-Au8(R) Pipeline
January 30, 2024
Via
Investor Brand Network
Researchers Propose New Way to Classify Parkinson’s Disease
January 29, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) VISIONARY-MS Trial Data May Support CNM-Au8(R) as Long-Sought-After Multiple Sclerosis Treatment
January 22, 2024
Via
Investor Brand Network
Ancient DNA Suggests Origins of Multiple Sclerosis in EU
January 17, 2024
Via
Investor Brand Network
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.